



Butrans[®] (buprenorphine) – First-time generic

- On May 31, 2017, [Teva launched](#) its authorized generic versions of Purdue Pharma's [Butrans \(buprenorphine\)](#) 5 mcg/hr, 10 mcg/hr, 15 mcg/hr, and 20 mcg/hr transdermal systems.
- Brand Butrans is also available as a 7.5 mcg/hr transdermal system.
 - Butrans, a schedule III controlled substance (C-III), is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
- Butrans carries a boxed warning for addiction, abuse, and misuse; life-threatening respiratory depression; accidental exposures; neonatal opioid withdrawal syndrome; and risks from concomitant use with benzodiazepines or other central nervous system depressants.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.